Jonathan Rozack
Family · Idaho Falls, IDNPI 1255429288
Payments from drug & device makers
Across 145 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$710
- Vanda Pharmaceuticals Inc.$255
- Novo Nordisk$198
- Lilly USA, LLC$182
- AstraZeneca$132
- Phathom Pharmaceuticals, Inc.$95
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,690 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 22 | $26,014 |
| EliquisApixaban | 29 | $23,635 |
| OzempicSemaglutide | 19 | $22,709 |
| JanuviaSitagliptin Phosphate | 27 | $12,766 |
| XareltoRivaroxaban | 15 | $9,701 |
| Repatha SureclickEvolocumab | 13 | $7,335 |
| Celecoxib | 27 | $2,436 |
| Duloxetine Hcl | 22 | $1,116 |
| Nebivolol Hcl | 22 | $965 |
| Cefdinir | 27 | $930 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $916 |
| Naproxen | 11 | $907 |
| Potassium Chloride | 32 | $881 |
| Ventolin HfaAlbuterol Sulfate | 11 | $848 |
| Levothyroxine Sodium | 58 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $132 | $26,01422 claims |
| PfizerEliquis | $88 | $23,63529 claims |
| Novo NordiskOzempic | $198 | $22,70919 claims |
| MerckJanuvia | $17 | $12,76627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.
Other family in Idaho Falls
- Amber MasseIdaho Falls$17K
- Samantha de Bruyn KopsIdaho Falls$10K
- Paula SanderlinIdaho Falls$10K
- Sunita SigdelIdaho Falls$9K
- Melissa KellyIdaho Falls$7K
- Kelsi RoundsIdaho Falls$6K
- Daniel HuntingIdaho Falls$6K
- Sunny RaichartIdaho Falls$5K
- Derek WhitmillIdaho Falls$5K
- Malinda McReaIdaho Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.